NCT07336836 (Renewal-NAD+) is a EARLY_PHASE1 clinical trial of LathMized TM NAD+ (LNAD+) in Health Adult Subjects, sponsored by BioNADrx Holdings, Inc. Bryleos.

Who is sponsoring NCT07336836?

NCT07336836 is sponsored by BioNADrx Holdings, Inc. Bryleos.

What drugs are being tested in NCT07336836?

Interventions in NCT07336836: LathMized TM NAD+ (LNAD+), Control (placebo).

What condition does NCT07336836 study?

NCT07336836 studies Health Adult Subjects, Healthy Participants.

Is NCT07336836 still recruiting?

NCT07336836 is currently completed. Last updated 13 January 2026.

Last reviewed 2026-01-13 · How we verify

NCT07336836: Renewal-NAD+

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort

Completed EARLY_PHASE1 Last updated 13 January 2026

What this trial tests

EARLY_PHASE1 trial testing LathMized TM NAD+ (LNAD+) in Health Adult Subjects in 60 participants. Completed in 4 June 2022.

Timeline

23 February 2022

Primary endpoint
4 June 2022

4 June 2022

Quick facts

Lead sponsor	BioNADrx Holdings, Inc. Bryleos
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	60
Start date	23 February 2022
Primary completion	4 June 2022
Estimated completion	4 June 2022
Sites	1 location across United States

Drugs / interventions tested

LathMized TM NAD+ (LNAD+)
Control (placebo)

Conditions studied

Health Adult Subjects — all drugs for Health Adult Subjects →
Healthy Participants — all drugs for Healthy Participants →

Sponsor

BioNADrx Holdings, Inc. Bryleos

Who can join

Adults 45 to 75, any sex, with Health Adult Subjects or Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this 5 day interventional study was to investigate the effects on multiple biological molecules (multi-omics) of Bryleos's commercially available oral LathMized™ Nicotinamide adenine dinucleotide (LNAD+) supplement in healthy adults aged 45-75 years. The main question to be answered was whether LNAD+ supplementation is associated with change in biological markers relevant to subjects' health. Also, the study determined whether this oral NAD+ formulation raised NAD+ levels including inside blood cells, after the 5 day treatment period, measured on post-treatment Day 1 (Day 6). Thus, the study compared NAD+ levels and impact on biological markers in the LNAD+ arm versus control placebo arm. Safety in this population was assessed using clinical laboratory tests, daily self-reporting of symptoms, and data from a wearable device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Health Adult Subjects

Currently open trials in the same condition.

NCT07534657 — A Study of JPH034 in Healthy Adult Participants · Phase 1 · recruiting
NCT07468981 — Movement Quality and Mechanical Properties of the Muscle · active not recruiting
NCT07433829 — Prefrontal Neuroplasticity and Coping Strategies in Healthy Population · NA · recruiting
NCT07465848 — Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis · NA · recruiting
NCT07199270 — A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07336836 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioNADrx Holdings, Inc. Bryleos
Last refreshed: 13 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07336836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing